Thrive Earlier Detection is a diagnostics company developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. Thrive utilizes machine learning technologies in its cancer detection platform, which is designed to detect cancer before symptoms occur.
"The acquisition of Thrive is a giant leap toward ensuring blood-based, multi-cancer screening becomes a reality and eventually, the standard of care," Exact Sciences CEO Kevin Conroy said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: